Stay ahead of the market with the latest news and analysis and maximize your portfolio’s potential
In a report released yesterday, Matt Phipps from William Blair reiterated a Buy rating on Axsome Therapeutics. The company’s shares closed last Friday at $178.69.
According to TipRanks.com, Phipps is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Axsome Therapeutics with a $181.91 average price target, representing a -0.8% downside. In a report issued on January 2, Truist Financial also maintained a Buy rating on the stock.
According to TipRanks.com, Massaro is ranked 0 out of 5 stars with an average return of
GeneDx Holdings has an analyst consensus of Strong Buy, with a price target consensus of $169.13, a 29.9% upside from current levels. In a report issued on December 22, Canaccord Genuity also maintained a Buy rating on the stock with a $170.00 price target.
